Lunit Inc. (KOSDAQ:328130)

South Korea flag South Korea · Delayed Price · Currency is KRW
39,250
+50 (0.13%)
At close: Dec 5, 2025
-35.02%
Market Cap1.15T
Revenue (ttm)76.69B
Net Income (ttm)-88.24B
Shares Out29.26M
EPS (ttm)-3,513.66
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume160,145
Average Volume389,032
Open39,300
Previous Close39,200
Day's Range38,500 - 39,800
52-Week Range34,150 - 85,800
Beta1.34
RSI50.16
Earnings DateNov 13, 2025

About Lunit

Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such a... [Read more]

Sector Technology
Founded 2013
Employees 307
Stock Exchange KOSDAQ
Ticker Symbol 328130
Full Company Profile

Financial Performance

In 2024, Lunit's revenue was 54.18 billion, an increase of 116.03% compared to the previous year's 25.08 billion. Losses were -82.42 billion, 124.0% more than in 2023.

Financial Statements

News

There is no news available yet.